Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT06859099

Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP

This study is a Phase 3 extension, global, multicenter open-label study. The purpose of this study is to evaluate long-term safety and efficacy of riliprubart in adult participants with chronic inflammatory demyelinating polyneuropathy (CIDP) who have completed Part B in 1 of 3 parent studies (PDY16744, EFC17236, or EFC18156) and wish to continue treatment with riliprubart. Up to approximately 300 participants will be enrolled to continue receiving treatment with riliprubart. The duration of participation for each participant will be up to approximately 4 years, including posttreatment follow-up. The treatment duration will be up to approximately 3 years. A participant who discontinues riliprubart treatment at any time during the study will be followed for safety for a minimum of 55 weeks after the last dose of riliprubart received.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Polyneuropathy, Inflammatory Demyelinating, Chronic Autoimmune Diseases Autoimmune Diseases of the Nervous System Chronic Disease Demyelinating Diseases Disease Attributes Immune System Diseases Nervous System Diseases Neuromuscular Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Peripheral Nervous System Diseases Polyneuropathies Polyradiculoneuropathy Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Investigational Site Number : 0320003, Buenos Aires, Argentina

Loading trial locations.

About this study

This is a single-arm study. All participants transitioning to Study LTS17261 will receive riliprubart weekly for up to 3 years, or until commercialization of riliprubart for the treatment of CIDP or termination of the riliprubart clinical development program for the treatment of CIDP, or the local availability of other options for long-term treatment with riliprubart, whichever comes first.

The total number of study visits will be 12.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  • Participants with chronic inflammatory demyelinating polyneuropathy (CIDP) currently receiving riliprubart who completed treatment in Part B of Study PDY16744, Study EFC17236, or Study EFC18156. (Participants receiving riliprubart in Part C of PDY16744 are eligible after completing the Part C End of Treatment visit.)
  • All participants must agree to use contraception methods during and after the study as required. Contraceptive use by men and women participating in the study should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Participant must be capable of giving signed informed consent as described in Appendix 1 of the protocol, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion criteria

Participants are excluded from the study if any of the following criteria apply:

  • Pregnancy, defined as a positive result of a highly sensitive urine or serum pregnancy test, or lactation
  • Clinical diagnosis of systemic lupus erythematosus (SLE)
  • History of any hypersensitivity to riliprubart or any of its components, or severe allergic or anaphylactic reaction to any humanized or murine monoclonal antibody
  • Any country-related specific regulation that would prevent the participant from entering the study
  • Accommodation in an institution because of regulatory or legal order; for instance, a prisoner or participant who is legally institutionalized
  • Unsuitability for participation as judged by the Investigator, whatever the reason, including: medical or clinical condition, potential risk of participant noncompliance with study procedures, or any other clinically significant change in the participants' medical condition

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Treatment and study plan

Riliprubart Prefilled Pen (PFP)

Drug

Pharmaceutical form: Solution Route of administration: Subcutaneous injection

Other names: SAR445088

Primary outcomes

  1. Number of participants having any AEs, SAEs, adverse events leading to treatment discontinuation, AESIs, and potentially clinically significant abnormalities (PCSAs) in safety laboratory tests, ECGs, and vital signs during the study period

    Time frame: Up to End of Study (approx. 4 years)

    adverse events: AEs, serious adverse events: SAEs, adverse events of special interest: AESIs, electrocardiograms: ECGs

Secondary outcomes

  1. Percentage of participants relapse-free since the first dose of riliprubart in the parent study (PDY16744, EFC17236, or EFC18156)

    Time frame: From first dose of riliprubart in parent study to end of treatment (up to approx. 7 years)

    To estimate the relapse-free rate, time to first relapse, defined as time from first dose of riliprubart in the parent study to the first relapse since riliprubart initiation, will be derived for each participant. Relapse since riliprubart initiation is defined as increase of 1 point or more in adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score relative to the visit for the first dose of riliprubart in the parent study.

  2. Percentage of participants experiencing improvement from baseline

    Time frame: From Baseline to 3 years

    Improvement is defined as a decrease of 1 point or more in adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score relative to baseline of the current study, Study LTS17261

  3. Change from baseline in adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score over time

    Time frame: From Baseline to 3 years

  4. Change from baseline in Inflammatory Rasch-built Overall Disability Scale (I-RODS) over time

    Time frame: From Baseline to 3 years

  5. Change from baseline in grip strength (kilopascals; dominant hand) over time

    Time frame: From Baseline to 3 years

  6. Change from baseline in Medical Research Council-Sum Score (MRC-SS) for muscle strength over time

    Time frame: From Baseline to 3 years

Sponsors and collaborators

Lead sponsor

Sanofi

Industry

Registry information

Official study title

Long-term Extension Study to Evaluate the Safety and Efficacy of Riliprubart (SAR445088) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Acronym: LTS

Important dates

Study start
2025
Primary completion
2029
Study completion
2029
First posted
Mar 5, 2025
Registry last updated
Jul 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.